Literature DB >> 28078112

Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern.

Humaid O Al-Shamsi1, Jeremy Jones2, Yazan Fahmawi3, Ibrahim Dahbour3, Aziz Tabash3, Reham Abdel-Wahab4, Ahmed O S Abousamra3, Kenna R Shaw5, Lianchun Xiao3, Manal M Hassan3, Benjamin R Kipp6, Scott Kopetz3, Amr S Soliman7, Robert R McWilliams2, Robert A Wolff3.   

Abstract

BACKGROUND: The frequency rates of mutations such as KRAS, NRAS, BRAF, and PIK3CA in colorectal cancer (CRC) differ among populations. The aim of this study was to assess mutation frequencies in the Arab population and determine their correlations with certain clinicopathological features.
METHODS: Arab patients from the Arab Gulf region and a population of age- and sex-matched Western patients with CRC whose tumors were evaluated with next-generation sequencing (NGS) were identified and retrospectively reviewed. The mutation rates of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC were recorded, along with clinicopathological features. Other somatic mutation and their rates were also identified. Fisher's exact test was used to determine the association between mutation status and clinical features.
RESULTS: A total of 198 cases were identified; 99 Arab patients and 99 Western patients. Fifty-two point seven percent of Arab patients had stage IV disease at initial presentation, 74.2% had left-sided tumors. Eighty-nine point two percent had tubular adenocarcinoma and 10.8% had mucinous adenocarcinoma. The prevalence rates of KRAS, NRAS, BRAF, PIK3CA, TP53, APC, SMAD, FBXW7 mutations in Arab population were 44.4%, 4%, 4%, 13.1%, 52.5%, 27.3%, 2% and 3% respectively. Compared to 48.4%, 4%, 4%, 12.1%, 47.5%, 24.2%, 11.1% and 0% respectively in matched Western population. Associations between these mutations and patient clinicopathological features were not statistically significant.
CONCLUSIONS: This is the first study to report comprehensive hotspot mutations using NGS in Arab patients with CRC. The frequency of KRAS, NRAS, BRAF, TP53, APC and PIK3CA mutations were similar to reported frequencies in Western population except SMAD4 that had a lower frequency and higher frequency of FBXW7 mutation.

Entities:  

Keywords:  Arab population; Somatic mutations; colorectal cancer (CRC); next-generation sequencing (NGS)

Year:  2016        PMID: 28078112      PMCID: PMC5177568          DOI: 10.21037/jgo.2016.11.02

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  130 in total

Review 1.  Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.

Authors:  Helena Linardou; Issa J Dahabreh; Dimitra Kanaloupiti; Fotios Siannis; Dimitrios Bafaloukos; Paris Kosmidis; Christos A Papadimitriou; Samuel Murray
Journal:  Lancet Oncol       Date:  2008-09-17       Impact factor: 41.316

2.  Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.

Authors:  Georgios Antonios Margonis; Yuhree Kim; Gaya Spolverato; Aslam Ejaz; Rohan Gupta; David Cosgrove; Robert Anders; Georgios Karagkounis; Michael A Choti; Timothy M Pawlik
Journal:  JAMA Surg       Date:  2015-08       Impact factor: 14.766

3.  Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer.

Authors:  Luisa Foltran; Giovanna De Maglio; Nicoletta Pella; Paola Ermacora; Giuseppe Aprile; Elena Masiero; Mariella Giovannoni; Emiliana Iaiza; Giovanni Gerardo Cardellino; Stefania Eufemia Lutrino; Micol Mazzer; Manuela Giangreco; Federica Edith Pisa; Stefano Pizzolitto; Gianpiero Fasola
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

4.  Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer.

Authors:  Lee Cheng Phua; Hui Wen Ng; Angie Hui Ling Yeo; Elya Chen; Michelle Shu Mei Lo; Peh Yean Cheah; Eric Chun Yong Chan; Poh Koon Koh; Han Kiat Ho
Journal:  Oncol Lett       Date:  2015-08-03       Impact factor: 2.967

5.  Prognostic significance of p53 mutations in colon cancer at the population level.

Authors:  Wade S Samowitz; Karen Curtin; Khe-ni Ma; Sandra Edwards; Donna Schaffer; Mark F Leppert; Martha L Slattery
Journal:  Int J Cancer       Date:  2002-06-01       Impact factor: 7.396

6.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

7.  Increased frequency of p53 mutation in sporadic colorectal cancer from cigarette smokers.

Authors:  Michiko Miyaki; Takeru Iijima; Reiko Ishii; Yumi Kita; Morio Koike; Toshio Kuroki; Takeo Mori
Journal:  Jpn J Clin Oncol       Date:  2002-06       Impact factor: 3.019

8.  Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes.

Authors:  Irene Lurkin; Robert Stoehr; Carolyn D Hurst; Angela A G van Tilborg; Margaret A Knowles; Arndt Hartmann; Ellen C Zwarthoff
Journal:  PLoS One       Date:  2010-01-21       Impact factor: 3.240

9.  Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery.

Authors:  Olfa Derbel; Qing Wang; Françoise Desseigne; Michel Rivoire; Pierre Meeus; Patrice Peyrat; Mattia Stella; Isabelle Martel-Lafay; Anne-Isabelle Lemaistre; Christelle de La Fouchardière
Journal:  BMC Cancer       Date:  2013-04-23       Impact factor: 4.430

10.  KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer.

Authors:  Chen Mao; Junhua Zhou; Zuyao Yang; Yafang Huang; Xinyin Wu; Hong Shen; Jinling Tang; Qing Chen
Journal:  PLoS One       Date:  2012-05-07       Impact factor: 3.240

View more
  18 in total

1.  Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients.

Authors:  Yajian Wang; Haijing Liu; Yingyong Hou; Xiaoyan Zhou; Li Liang; Zhihong Zhang; Huaiyin Shi; Sanpeng Xu; Peizhen Hu; Zuyu Zheng; Rui Liu; Tingdong Tang; Feng Ye; Zhiyong Liang; Hong Bu
Journal:  Virchows Arch       Date:  2018-04-28       Impact factor: 4.064

Review 2.  Familial/inherited cancer syndrome: a focus on the highly consanguineous Arab population.

Authors:  Fawz S AlHarthi; Alya Qari; Alaa Edress; Malak Abedalthagafi
Journal:  NPJ Genom Med       Date:  2020-02-03       Impact factor: 8.617

3.  KRAS/NRAS/BRAF Mutation Rate in Saudi Academic Hospital Patients With Colorectal Cancer.

Authors:  Samah Saharti
Journal:  Cureus       Date:  2022-04-22

Review 4.  Back to the Colorectal Cancer Consensus Molecular Subtype Future.

Authors:  David G Menter; Jennifer S Davis; Bradley M Broom; Michael J Overman; Jeffrey Morris; Scott Kopetz
Journal:  Curr Gastroenterol Rep       Date:  2019-01-30

Review 5.  Functional significance and therapeutic implication of ring-type E3 ligases in colorectal cancer.

Authors:  L Liu; C C Wong; B Gong; J Yu
Journal:  Oncogene       Date:  2017-09-18       Impact factor: 9.867

6.  Identification of different mutational profiles in cancers arising in specific colon segments by next generation sequencing.

Authors:  Duarte Mendes Oliveira; Carmelo Laudanna; Simona Migliozzi; Pietro Zoppoli; Gianluca Santamaria; Katia Grillone; Laura Elia; Chiara Mignogna; Flavia Biamonte; Rosario Sacco; Francesco Corcione; Giuseppe Viglietto; Donatella Malanga; Antonia Rizzuto
Journal:  Oncotarget       Date:  2018-05-08

7.  Combined assessment of the TNM stage and BRAF mutational status at diagnosis in sporadic colorectal cancer patients.

Authors:  José María Sayagués; Sofía Del Carmen; María Del Mar Abad; Luís Antonio Corchete; Oscar Bengoechea; María Fernanda Anduaga; María Jesús Baldeón; Juan Jesús Cruz; Jose Antonio Alcazar; María Angoso; Marcos González; Jacinto García; Luís Muñoz-Bellvis; Alberto Orfao; María Eugenia Sarasquete
Journal:  Oncotarget       Date:  2018-05-08

8.  Frequency of NRAS Gene Mutation in Wild Type KRAS and BRAF Colorectal Cancers; a Single Center Study.

Authors:  Hooria Momenzadeh; Mitra Mirzai; Zahra Jowkar; Bita Geramizadeh
Journal:  Middle East J Dig Dis       Date:  2018-01-06

9.  Silencing Smad4 attenuates sensitivity of colorectal cancer cells to cetuximab by promoting epithelial‑mesenchymal transition.

Authors:  Zhenlv Lin; Lin Zhang; Junfeng Zhou; Jiantao Zheng
Journal:  Mol Med Rep       Date:  2019-08-21       Impact factor: 2.952

10.  Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Non-Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing.

Authors:  Zahra Shajani-Yi; Francine B de Abreu; Jason D Peterson; Gregory J Tsongalis
Journal:  Neoplasia       Date:  2018-02-16       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.